From the editor:

In a recent article, GenomeWeb News reports that Novartis Molecular Diagnostics focuses on companion diagnostics as key strategic direction. By “… moving into the companion diagnostics space, Novartis has joined a growing list of firms that believe that market could become a major business opportunity, though it may take several years for it to happen. Like its Swiss competitor, Roche, Novartis has expansive pharmaceutical programs that lend themselves to companion diagnostic efforts” concludes Tony Fong, the author of the article.

It is going to be interesting to see what kind of companion diagnostics these efforts will yield. Don’t be surprised if image-based diagnostics will play an essential role.